Join the BrightTALK forensic science community for access to online forensics training from respected professionals in the field. Study forensic science online to learn necessary skills for trace evidence in forensics, liquid and gas chromatography and sample preparation. You can also attend live webinars to interact with forensic scientists and have your questions answered.
Does western blotting give you more trouble than expected? Do you feel like your precious samples are being wasted on bad westerns? Join us and find out how you can improve your western blots! In this seminar, you will learn general guidelines for performing and troubleshooting your westerns, such as:
• Choice of different blotting membranes
• Parameters affecting blotting efficiency
• Conditions for optimizing your immunodetection
• Information on SNAP i.d.® 2.0 system: A faster way to perform immunodetection
A digital debate analysing the future for biologics in the UK and the factor affecting market access in this territory. Our expert panel will cover a number of key topics including:
•Are the savings offered by biosimilars being used to innovate and take advantage of the exciting new biologic technologies or just filling in the NHS potholes?
•Will the industry continue to invest in cutting-edge research if the UK is not prepared to fund access to it
•In a post-Brexit world how can the UK continue to be a global leader at the cutting edge of biologics research?
Understanding the movements, modifications and interactions of proteins within a cell is key to unraveling the fundamental tenets of biology. However, the low-level expression of many proteins, combined with the transient nature of their interactions and movements, makes analyzing and understanding these processes quite difficult. Duolink® PLA, which is based on the principles of the proximity ligation assay (PLA), offers a solution to overcome these hurdles and to study the actions of endogenous proteins within cells and tissues. Combining the specificity of antibodies with the sensitivity afforded by rolling circle amplification, Duolink® PLA allows you to detect, visualize, and quantitate proteins and their interactions (even single events) where they happen within cells or tissue, all without overexpression or genetic manipulation. This seminar will cover the basic assay principle and advantages of the Duolink® PLA technology, and discuss recent applications and developments of the technology that make it an excellent tool to understand the fundamental mechanisms of biology, as well as disease states. Applications of Duolink® PLA include the investigation of cellular responses to varying stimuli, receptor dimerization and signalling cascades, post-translational modifications, and regulation of protein expression. New developments include use in flow cytometry and multiplexed detection.
78% of employees pose critical threats to your security, says a study from the Ponemon Institute (1). Whether they’re disgruntled or simply make a mistake, your employee “insiders” regularly put your most confidential data at risk every day.
According to Ponemon, innocent accidents cause more security incidents than intentional or malicious acts – even your best employees put your data at risk. So how do you best enable your teams to access the data they need while keeping it safe?
Hear how a real-world CISO plans, implements and manages an insider threat program. Find out how you enable employees to use disruptive, transformative technology while keeping sensitive data safe. Gain practical insights into planning and implementing an Insider Threat program, including employee education and adoption and executive sponsorship.
(1) “Privileged User Abuse & The Insider Threat,” Ponemon Institute 2014.
In 2018, the General Data Protection Regulation (GDPR) will require EU organizations to meet strict standards and processes to protect personal data. Non-compliance with the GDPR can cost you a fortune, but being in compliance can save you one. Recent estimates put business savings at about €2.3 billion annually.
Join Mike Osterman (Osterman Research) and Mike Smart (Forcepoint Product & Solutions Director, EMEA) as they discuss how to become GDPR compliant by implementing organizational and technical solutions.
This on-demand webcast will explore GDPR security responsibilities and obligations, including:
-Data subject consent
-Data discovery, cataloguing and classifying
-Data breach identification and notification
-Cloud storage and sharing services
As we enter into the final 12 months before the GDPR becomes applicable, take this opportunity to set urgency as to how your organisation must be prepared for the new regulation from experts in data protection and privacy law.
Rosemary Jay, Senior Consultant Attorney from Hunton & Williams, provided guidance and outlook shared from supervisory authorities across the EU to the Article 29 Working Party. Additionally, Forcepoint Deputy CISO Neil Thacker discussed how organisations can use technology to help meet the requirements of the GDPR.
This interactive webcast explored ways to:
-Comply with offering individuals rights to access their personal data, respond to Subject Access Requests, and the Right to Erasure/be Forgotten
-Explore organisational and technical controls that are considered adequate by the supervisory authorities
-Demonstrate organisational accountability to: inventory, map, manage and control data flows and respond to data incidents
78% of employees pose critical threats to your security, says a study from the Ponemon Institute. Whether they’re disgruntled or simply make a mistake, your employee “insiders” regularly put your most confidential data at risk every day. According to Ponemon, innocent accidents cause more security incidents than intentional or malicious acts – even your best employees put your data at risk. So how do you best enable your teams to access the data they need while keeping it safe?
While your IT system can be a witness, victim or enabler, insider threats are more than a technology problem. Policy, process, controls, risk management, auditing and monitoring all play critical roles in managing this invisible vulnerability. Watch this webcast to learn about managing and mitigating insider threats within your organization.
Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans. Biopharma companies must take into account a multitude of factors when considering physician prescribing behaviors, and need a more integrated "pull-through" strategy across their teams, from managed markets, to marketing, to field sales. Just as an engine needs a steady supply of fuel to run efficiently, prescriber-facing teams – the commercial engine of life sciences companies – need market access data and insights to accelerate brand success. Today, the challenge is optimizing this fuel supply, as market access and commercial teams often operate in a siloed way with regards to data, market changes and insights.
Join a vibrant conversation with industry leaders to discuss how the industry is changing and adapting to operationalize market access pull-through for improved commercial success.
In this webinar, Eloísa Urrechaga, M.D., Ph.D., will discuss the importance of iron status assessment in accurately diagnosing and treating anemia. The complexities of anemia require solutions that will help meet the daily challenges of distinguishing iron deficiency anemia (IDA) and isolating anemia of chronic diseases (ACD) from the combined state of IDA/ACD.
After this webinar, you will be able to:
• Discuss current advancements in anemia diagnosis
• More clearly understand the role of accurate iron status assessment
• Cite the latest research experience with Beckman Coulter analyzers in assessing iron status
P.A.C.E. credit is available for your participation.*
Eloísa Urrechaga, M.D., Ph.D., has more than 30 years of experience in hematology and laboratory medicine. She is a specialist in clinical analysis technology, robotics in hematology, iron and anemia, erythropoiesis and glycohemoglobin. Currently, Dr. Urrechaga is responsible for the hematology laboratory at the Hospital Galdakao-Usansolo in Spain.
Dr. Urrechaga contributes her expertise to the Spanish Science and Innovation Ministry by assessing new technologies. She also provides counsel to the Health Research Council for the validation of research projects in the Czech Republic and Argentina. In addition, she is a member of several international organizations, such as the World Health Organization Guideline Development Group and European Network for Rare and Congenital Anaemias. Dr. Urrechaga also serves as an editorial board member and scientific reviewer for a number of journals.
*Beckman Coulter Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. These credits are recognized by the State of California. At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.
For the past two decades, Solid Phase Microextraction (SPME) has represented a convenient alternative to conventional sample prep procedures. SPME allows the simultaneous extraction and enrichment of analytes of interest from a given matrix in a single step while avoiding, or drastically minimizing, the use of organic solvents and time-consuming cleanup procedures.
Like any other analytical method, the various parameters governing the SPME process need to be carefully optimized in order to achieve robustness and sensitivity. However, certain aspects of SPME method development are often overlooked by many users, leading to unsatisfactory performance of the technique.
This webinar will shed light into several aspects of SPME method development. The presentation will include a theoretical explanation of SPME fundamentals and practical suggestions to overcome common errors and bias encountered when using SPME.
The webinar is divided in three main sections: 1) optimization of extraction conditions 2) matrix modifications 3) optimization of desorption conditions for gas and liquid chromatography. Each section is divided in various subsections dedicated to each parameter affecting the performance of the SPME technique. The webinar attendees will be guided through comprehensive understanding of the technology and the critical parameters that influence the extraction process with practical examples from already existing methods.
The world of the field force is changing. Increased digitalisation, powerful new tools and a growing expectation that they ‘conduct’ multiple channels means new skills, ways of working, and even thinking, are needed.
This shift will radically change the structure of the traditional Pharma organization. Differences between HQ and local offices will become less pronounced as the field force gains the ability to deploy highly tailored, right-on-time content, in the best possible format for individual physicians.
Find out more about how the time of the Multichannel Rep is now, how upskilling and reskilling are the buzzwords for new engagement models, and how not to have your field force being left behind in the digital race!
•Getting the right digital tools into the hands of reps
•How to evaluate what the best channels for your situation are
•Finding out what good looks like
•How to engage your field force, manage the change, and sustain their motivation
Lung cancer is the most commonly diagnosed non-skin cancer in the United States. Each year, over 222,000 people are diagnosed with lung cancer, and over 150,000 succumb each year to the illness, making it also the deadliest cancer in the country. With constant advancement of treatment options, the importance of accurate diagnosis and detection of lung cancer becomes more and more relevant to the survival of the patient. Immunohistochemistry has served as the catalyst for these advancements in lung cancer diagnosis. This presentation covers many of the basic science, facts, and statistics of lung cancer, as well as the utility of immunohistochemical testing with markers such as TTF-1, napsin A, desmoglein-3, and p40 in the accurate diagnosis and survival rates of lung cancer.
Growing patient influence combined with new technologies and the requirements of new reimbursement models means clinical research is undergoing rapid transformation. Industry is being compelled to move towards more patient centric solutions to keep up with these changes. With healthcare stakeholders in agreement that patient engagement is key to realising the value of clinical trials, regulators, sponsors, CROs, research funders and publishers are all moving towards more patient-focused models.
With the advent of new methodologies, such as electronic data sources and medical records, recruiting patients for trials now demands extensive collaboration between patients and trial centers to effectively and efficiently run trials. The patient has never been more important.
To mark Clinical Trials Awareness Week, pharmaphorum, in partnership with INC, will present a live webinar exploring the challenges and solutions of the current environment and how collaboration can benefit research participation, as well as the vital role the patient advocate plays in these matters.
In typical analytical workflows, sample preparation accounts for over 60% of the time taken to generate results and 30% of any errors generated. To help analytical chemists maintain the cornerstones of all analytical processes, namely; speed, specificity, sensitivity, and reproducibility, considerable resources have been devoted to the development of new and unique technologies in the sample preparation field. With specific reference to solid phase extraction and solid phase microextraction, this presentation will outline new technologies and techniques developed in sample preparation for food analysis.
The life sciences landscape is moving at a rapid pace, which in turn is increasing the demands on marketers to create innovative, digital content faster while maintaining industry compliance.
Veeva Systems recently conducted an annual industry study, focused on content and digital asset management within life sciences. Gleaned from the experiences and opinions of leaders across the life sciences industry, the research uncovers current practices and the industry’s need for more advanced approaches for global marketing and regulatory compliance.
Join this webinar to hear the key insights from the survey results, and discuss key highlights with host David Bennett, VP Commercial Content Strategy Europe, Veeva.
From this webinar you will:
– Learn the current state of commercial content and digital asset management in life sciences promotions
– Garner an understanding of how your organization compares to the industry
– Understand how to accelerate your content across the digital supply chain
Live Webinar on April 4 at 5pm CET
Life Sciences is an industry full of established, large companies with significant barriers to entry and often long legacies of success. But the weather is changing – and the structures and strategies which have kept these enterprises safe may soon become liabilities. What is only just becoming clear, though, is how fast this is happening. Along all key areas of the value chain, new & nimble competitors are entering the scene - and they are playing a totally different game.
Find out more about these disruptive trends, get the highlights of our second ‘Healthcare Disruption Tour’, which went to the heart of the action in Jan 2017, and learn why pharma should take note…and how it can best prepare & organize for this tsunami.
• Key trends in healthcare disruption
• Impressions from the second healthcare disruption tour
• Embedding disruption in pharma organisations
CRISPR Cas9 nucleases have revolutionized the field of gene editing and high-throughput lentiviral screens continue to hold ever-increasing promise for both basic research and development of future therapies to benefit human health. Even with such powerful technologies at hand, researchers new to the field may find the screening of multiple targets to be challenging and time-consuming. This webinar discusses the Evotec partnership with Life Science Business of Merck KGaA, Darmstadt, Germany and the screening services for drug discovery.
2017 is once again a year of significant change for pharma market access in Europe, with affordability on the agenda for almost every country in the region. There is a move toward greater collaboration in health technology assessment and more transparency between countries for pricing, therapeutic protocols and and details of negotiations with drug manufacturers. We also see member states working to understand the process of enabling cost-effective patient access to personalised and high-cost treatments, such as new oncology combination therapies, antibiotics and stem cell therapies, which offer the promise of efficacy in key disease areas.
With market access being referred to as the “fourth hurdle” in drug development (beyond efficacy, safety and quality), it is vital that the requirements for both approval and access are addressed early in the process. Parallel scientific advice from HTA bodies and regulators is increasing to deliver tangible and successful strategies, but is the process smooth enough to overcome the challenges from both sides?
pharmaphorum in partnership with DIA will be hosting an expert panel debating the best way forward for life sciences companies, payers and providers in this emerging European market access paradigm.
Join our webinar to hear from experts in industry and healthcare discussing the challenges and solutions of access in the changing European market.
Topics up for discussion include:
•Integrating HTA and regulatory strategy – the best way forward
•Regional variation and implication – how to efficiently and effectively navigate EU market access
•Proving value – how to leverage real world evidence to meet increasing demands for observational data
•Future proofing market access – how to improve upon evidence generation and use technology effectively and competitively
In our webinar, Identifying Men with Prostate Cancer—The Role of phi and Other Biomarkers, Dr. E. David Crawford will discuss key issues that challenge a physician's ability to make informed decisions regarding whom to biopsy for prostate cancer. After the webinar, you will be able to:
• Understand the historical perspective and controversy regarding prostate-specific antigen (PSA) screening
• Improve your interpretation of a PSA result
• Use biomarkers, such as Prostate Health Index (phi), to reduce negative biopsies and have more confidence in the decision to biopsy
• Understand how the phi score, combined with family and patient history, can determine patient management decisions
Dr. Crawford is an internationally renowned urologist and distinguished endowed professor of surgery, urology and radiation oncology. He also serves as the head of the section of urologic oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
Dr. Guido Vranken and Lobke Tremmerie discuss how to implement Bulls XB algorithm, which uses RBC indices to create a weighted moving average of patient sample results, to statistically monitor hematology results. This unique algorithm, offered on Beckman Coulter hematology instruments, allows users to monitor result quality without additional reagents, software licenses or costs. Laboratories worldwide can implement this simple, powerful tool to enhance results and improve compliance.
P.A.C.E. credit is available for your participation.*
Presenters: Guido Vranken, Ph.D, has been working with customers for over 30 years across different disciplines, including protein chemistry, immunoassay and hematology. He specializes in conducting internal and external validation studies. Dr. Vranken spent three years as a lecturer on statistics at the University of Ghent. Lobke Tremmerie earned her environmental engineering degree from the University of Ghent in 2002. She first became an electrophoresis and nephelometry sales engineer at Analis, Beckman Coulter’s exclusive Belgian distributor. Following her true passion, she transferred into the hematology division in 2004. Ms. Tremmerie currently serves as Analis’ cellular biology product marketing manager.
With rising healthcare costs, more informed and engaged patients, and advancing technology, health wearables have seen a significant uptake in recent years. However, the full potential of health wearables has yet to be recognised and there are still challenges to be resolved. What needs to be done on the regulatory, technical and healthcare side to take health wearables to the next level?
In this webinar, experts from the life sciences and technology industries discuss their views on the current state and future developments of health wearables, including:
– The user perspective: perception, adoption and expectations today and tomorrow
– The technology perspective: biggest successes and most room for improvements
– The societal and regulatory perspective: cost and risks versus benefits and opportunities
How do you know when your result parameters are set to their most efficient ranges?
In part two of our three-part webinar series, Dr. Michael Samoszuk highlights the correlative relationships between urine chemistry data and urine microscopy data on Beckman Coulter’s Iris iRICELL3000. Learn how these correlations can help you optimize the customizable auto-release function and reduce your laboratory’s manual workload.
Michael Samoszuk, M.D., vice president and chief medical officer of Beckman Coulter Diagnostics, is a graduate of Harvard Medical School, Boston, and completed his postgraduate training at Brigham and Women's Hospital, Boston; University of California, San Francisco; and University of Southern California, Los Angeles. As an experienced chief medical officer, director of hemapathology and associate professor of pathology and radiology, Dr. Samoszuk contributes his expertise to Beckman Coulter’s diagnostics division. His guidance supports product and process developments as well as performance enhancements with patients and clinicians in mind.
Working with QuintilesIMS, we present a digital debate which will offer modellling-based insights into the future of hepatitis C treatment.
Key topics to be discussed include:
– The burden of HCV
– The current market landscape
– The current patient access model and its impact on budget
– Cost efficiencies shown by modelling
– Cure versus lifetime treatment costs
What does it mean when you have positive urine chemistry red blood cell (RBC) results but see no RBCs under the microscope?
In part one of our webinar series, Dr. Michael Samoszuk illustrates which properties of RBCs interact chemically with iRICELL3000 urine test strips to cause positive urine chemistry results, even in the absence of whole RBCs under the microscope.
Watch this webinar to learn more about the cause of contrasting results between urine chemistry and urine microscopy and understand why your results may still be in perfect correlation.
Michael Samoszuk, M.D., vice president and chief medical officer of Beckman Coulter Diagnostics, is a graduate of Harvard Medical School, Boston, and completed his postgraduate training at Brigham and Women's Hospital, Boston; University of California, San Francisco; and University of Southern California, Los Angeles. As an experienced chief medical officer, director of hemapathology and associate professor of pathology and radiology, Dr. Samoszuk contributes his expertise to Beckman Coulter’s Diagnostics His guidance supports product and process developments as well as performance enhancements with patients and clinicians in mind.
The CRISPR/Cas genome editing system has revolutionized almost every aspect of the life science industry. Until recently, the most used formats for this technology have been plasmids, mRNA, or lentivirus. Each reagent has been successful in its own right, however, each approach has limitations. SygRNATM, the two-part synthetic crRNA and tracrRNA, increases the pace of research, decreases costs, and can be used with Cas9 protein, Cas9 mRNA and Cas9 expressing cells/models.
This webinar discusses the development of the SygRNATM system, protocol optimization, and proposes workflows that enable scientists to quickly incorporate CRISPR technologies into their research.
With a wealth of market and regulatory changes impacting the medtech sector, it’s time for digital technology to steer the direction of your future business. This expert webinar will evaluate how to strategically embed digital within your own organisation and explore the challenges and the opportunities for transforming customer relationships, driving commercial outcomes.
– Respond to the changing regulatory environment: how technology empowers your business
– Build a business case for digital transformation and gain organisational support
– Strengthen your customer relationships and improve engagement in a diverse payer landscape
– Learn from pharma (and other industries) to find opportunities and avoid pitfalls
– Measure impact and return on investment from digital engagement
The benefits of three dimensional (3D) cell culture are widely appreciated. More cell-based technologies are now becoming available that enable researchers to preserve the native 3D structure of cells in vitro. These can be broadly divided into three areas: aggregate-based methods; hydrogels and extra-cellular matrices; and inert scaffold-based technologies. Each has strengths and weaknesses and there is no one technology that satisfies all applications. Tissues in the body are mostly composed of different cell types that are often highly organized in relation to each other. Often cells are arranged in distinct layers that enable signalling and cell-to-cell interactions. Alternatively in tumours, cancer cells form aggregates and tissue masses composed of different cell types. Recreation of these types of architecture will significantly evolve 3D cell culture to a new level where real tissue-like structures can be generated in vitro.
This webinar will review the alternative approaches available to researchers and provide an overview of their capabilities and example applications. More sophisticated models are developing as 3D cell culture technology becomes established and accepted as a means of creating more physiologically relevant cell-based assays. Methods that are relatively straightforward to use and that recreate the organized structure of real tissues will become valuable research tools for use in discovery, validation studies, and modelling disease.
Key areas covered:
• 2D vs 3D cell culture debate
• Review of alternative approaches and the development of new technologies
• Challenges facing 3D culture methods, in terms of technologies available and methods used
• Showcase applications where 3D technology makes a difference
• Future perspective for 3D cell culture technology and further development
Solid phase microexatraction or SPME is a green method for extraction of analytes out of a sample. Since SPME is a non-exhaustive extraction technique, some analysts believe that SPME is not quantifiable. This presentation will provide basic information for developing a method to extract and quantify analytes using SPME. Examples will be given on the extraction and quantification of analytes out of various matrices, and SPME will be compared to other extraction techniques such as QuEChERS and SPE. In this webinar, we will discuss some new SPME technologies such as SPME-OC (over-coated) fibers and BioSPME that help to isolate and quantify analytes from interfering compounds in the matrix. Guidelines will be provided for enhancement of precision using SPME.
Join us to find out about the results of the 2017 Multichannel Maturometer. The ninth version of this industry-renowned survey illuminates some of the big changes sweeping through the Pharma industry, as well as highlighting some trends which are still lagging.
Questions which will be answered include:
• Is senior leadership still on the fence for digital?
• Marketing budgets – how are they changing?
• How satisfactory are those in the industry finding digital offerings?